A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD)

NCT00626535 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Symptomatic Gastroesophageal Reflux Disease (sGERD)

Interventions

DRUG: Esomeprazole
DRUG: Matching placebo

Sponsor

AstraZeneca